Results 181 to 190 of about 698,336 (388)
Targeting the EphA2 pathway: could it be the way for bone sarcomas?
Cell Communication and SignalingBone sarcomas are malignant tumors of mesenchymal origin. Complete surgical resection is the cornerstone of multidisciplinary treatment. However, advanced, unresectable forms remain incurable.
Giorgia Giordano +4 more
doaj +1 more source
Clinical Surgical OncologyIntroduction: For patients affected by extremity or trunk soft-tissue sarcomas (STS) large resections might be needed to achieve negative margins. This is a common scenario especially in locally advanced or recurrent tumors often within a pre-irradiated ...
Sergio D. Quildrian +3 more
doaj +1 more source
Advanced Science, EarlyView.This review summarizes recent advances in the spatiotemporal dynamics of the tumor microenvironment (TME). It highlights the roles of diverse immune and stromal cell populations, spatial architecture of the TME, as well as the gut and tumor microbiota in influencing responses to immune checkpoint inhibitors (ICIs), by integrating insights from single ...
Yuanyuan Zhang, Zhihua Liu
wiley +1 more source
Journal of the International AIDS SocietyIntroduction Differentiated service delivery (DSD) models have been widely implemented for patients in stable HIV care. However, DSD has rarely been offered to newly diagnosed patients.
Jean Bernard Marc +18 more
doaj +1 more source
In Situ Vaccines in the Era of Cancer Immunotherapy: Conceptual Innovation and Clinical Translation
Advanced Science, EarlyView.In this review, the basic concepts of in situ vaccination are discussed, its advantages over conventional vaccines, and key historical milestones, from the first use of Coley's toxins to the most recent FDA‐approved in situ vaccine for bladder cancer.
Yiru Shi +4 more
wiley +1 more source
SARCOMA SURROUNDING A CONCRETION IN THE VERMIFORM APPENDIX; EXCISION OF CÆCUM; RECOVERY. [PDF]
, 1893 Hastings Gilford
openalex +1 more source
Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers
Journal of Hematology & OncologySoft tissue and bone sarcomas are a heterogenous group of uncommon mesenchymal tumors with high unmet needs for novel therapeutic and diagnostic strategies. Despite many challenges that persist, innovative therapeutics are emerging.
Minggui Pan +4 more
doaj +1 more source
Tumor Microenvironment‐Responsive Nanomedicines for Potentiating Cancer Immunotherapy
Advanced Science, EarlyView.Strategies for TME‐responsive Nanomaterials to Potentiate Cancer Immunotherapy. Abstract Immunotherapy has emerged as a transformative paradigm in oncology, yet its clinical efficacy remains constrained by the immunosuppressive tumor microenvironment and inadequate spatiotemporal control of existing modalities, resulting in suboptimal patient response ...
Qianqian Huang +7 more
wiley +1 more source